Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-09-12
2006-09-12
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S043000, C514S045000, C514S048000, C514S049000, C514S052000, C514S885000, C424S001110, C424S001730, C424S001770, C424S009810, C424S278100, C424S280100, C536S022100, C536S023100, C536S024500, C536S025600
Reexamination Certificate
active
07105495
ABSTRACT:
The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.
REFERENCES:
patent: 5149798 (1992-09-01), Agrawal et al.
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5719271 (1998-02-01), Cook et al.
patent: 5856462 (1999-01-01), Agrawal
patent: 5968909 (1999-10-01), Agrawal et al.
patent: WO 97/33992 (1997-09-01), None
patent: WO 98/49288 (1998-11-01), None
patent: WO 01/12804 (2001-02-01), None
Liang et al., J. Clin. Invest., vol. 98, pp. 1119-1129, 1996.
Moldoveanu et al., Vaccine, vol. 16, pp. 1216-124, 1998.
Yu et al., J. Med. Chem. vol. 45, pp. 4540-4548, 2002.
Clivio et al., “Synthesis and Purification of Oligonucleotides Containing Sulfur Substituted Nucleobases: 4-Thiouracil, 4-Thiothymine, and 6-Mercaptopurine”, Tetrahedron Letters, vol. 33, No. 1, pp. 65-68, 1992.
Agrawal, Methods in Molecular Biology, Protocols for Oligonucleotides and Analogs, 20:165-189, (1993).
Agrawal et al., Curr. Op. in Biotech., 6:12 (1995).
Khorana et al., J. Molec. Biol. 72:209 (1972).
Reese, Tetrahedron Lett. 34:3143-3179 (1978).
Beaucage et al., Tetrahedron Lett. 22:1859-1862 (1981).
Agrawal et al., Tetrahedron Lett. 28:3539-3542 (1987).
Connolly et al., Biochemistry 23:3443 (1984).
Jager et al., Biochemistry 27:7237 (1988).
Agrawal et al., Proc. Natl. Acad. Sci. USA 85:7079-7083 (1988).
McIntyre et al., Antisense Res. Dev. 3:309-322 (1993).
Kuramoto et al., Jpn. J. Cancer Res. 83:1128-1131 (1992).
Krieg et al., Nature 371:546-549 (1995).
Liang et al., J. Clin. Invest. 98:1119-1129 (1996).
Moldoveanu et al., Vaccine 16:1216-124.
McCluskie et al., The Journal of Immunology 161:4463-4466 (1998).
Zhao, Q. et al., Bioorganic & Medicinal Chemistry, “Site of Chemical Modifications in CpG Containing Phosphorothioate Oligonucleotide Modulates Its Immunostimulatory Activity”, pp. 3453-3459 (1999).
Krieg, Arthur M., Applied Antisense Oligonucleotide Technology, “Leukocyte Stimulation by Oligodeoxynucleotides”, pp. 431-448 (1998).
Kandimalla, E.R. et al., Bioorganic & Medicinal Chemistry, “Effect of chemical Modifications of Cytosine and Guanine in a CpG-Motif of Oligonucleotides: Structure-Immunostimulatory Activity Relationships”, pp. 807-813 (2001).
Ekambar, D.Y. et al., Bioorganic & Medicinal Chemistry, “Modulation of Immunostimulatory Activity of CpG Oligonucleotides by Site-Specific Deletion of Nucleobases”, pp. 2263-2267 (2001).
Khorana et al. “Studies on Polynucleotides”, J. Molec. Biol. 72:209 (1972).
Agrawal et al., “Oligodeoxynucleotides Methylphosphonates: Synthesis and Enzymic Degradation”, Tetrahedron Lett. 28(31):3539-4542 (1987).
Zon et al., “Phosphorothioate Oligonucleotides” Oligonucleotides and Analogues: A Practical Approach, pp. 87-108 (1991).
Agrawal, “Antisense Oligonucleotides and Antiviral Agents”, Trends in Biotechnology, 10:152-158 (1992).
Zon, “Protocols for Oligonucleotides and Analogs,” Methods in Molecular Biology, 20:165-189 (1993).
Agrawal et al., “Antisense Therapeutics: Is It as Simple as Complementary Base Recognition?” Mol. Med. Today 6:72-81 (2000).
Agrawal Sudhir
Kandimalla Ekambar R.
Idera Pharmaceuticals Inc.
Jiang Shaojia Anna
Keown & Associates
McIntosh Traviss C.
LandOfFree
Modulation of oligonucleotide CpG-mediated immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of oligonucleotide CpG-mediated immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of oligonucleotide CpG-mediated immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3532948